Lipocine Inc. (LPCN)
Nasdaq · Healthcare · Biotechnology
$2.07+0.98%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $17.1M
- 52-week range
- $1.81 – $12.37
- 52-week change
- −36.34%
- EPS (trailing)
- −$1.85
Fiscal year to Dec 2025
- Revenue
- $2.0M (−82.35%)
- Net income
- −$9.6M
- Operating margin
- −524.7%
- Diluted EPS
- −$1.69
From the company’s annual report on SEC EDGAR.
About Lipocine Inc.
Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs using its proprietary delivery technology. The company offers TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. It also develops LPCN 1154 (BRLIZIO), an oral neuro-steroid in a Phase 3 pivotal trial for postpartum depression; LPCN 1148, a prodrug of testosterone and testosterone laurate that has completed a Phase 2 trial for the management of decompensated cirrhosis; LPCN 1107, an oral hydroxy progesterone caproate product that has completed a Phase 2 trial for the prevention of recurrent preterm birth; LPCN 1144, an oral prodrug of bioidentical testosterone that has completed a Phase 2 trial for pre-cirrhotic non-alcoholic steatohepatitis; and LPCN 2401, an oral formulation comprising a proprietary anabolic androgen receptor agonist that is in a Phase 2 trial to manage incretin mimetic use in obesity management.
Headquarters: Salt Lake City, United States · 14 employees · lipocine.com